leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...1920212223242526272829...235236»
  • ||||||||||  leucovorin calcium / Generic mfg.
    Journal:  Towards voltammetric point of care detection of leucovorin. (Pubmed Central) -  Apr 2, 2024   
    A low cost, easy-to-use and portable sensor has been developed and successfully employed for the detection of LV over the linear range 0.5-30 ?M which represents the therapeutically relevant concentrations for LV within artificial urine without any prior sample preparation required with a limit of detection of 2.63 ?M and initial investigations into saliva and serum as biological matrices. The developed sensor describe herein exhibits a proof-of-concept for the engagement of such electrochemical sensors as point-of-care devices, where the sensors ease of use and removal of time-consuming and complex sample preparation methods will ultimately increase its usability by physicians, widening the avenues where electrochemical sensors could be employed.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal:  The MUC1-HIF-1? signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling. (Pubmed Central) -  Apr 1, 2024   
    By utilizing organoid and orthotopic pancreatic cancer mouse models, we observed that targeting SAT1 with pentamidine improved the efficacy of FOLFIRINOX, suggesting that the combination may represent a promising therapeutic strategy against pancreatic cancer. This study provides insights into the interplay between MUC1 and polyamine metabolism, offering potential avenues for the development of treatments against pancreatic cancer.
  • ||||||||||  Review, Journal:  Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver. (Pubmed Central) -  Apr 1, 2024   
    Other combinations such as adagrasib-cetuximab, divarasib-cetuximab, or FOLFIRI-panitumumab-sotorasib have also shown a meaningful response rate and are currently under evaluation...In this setting, liquid biopsy emerges as a critical tool to characterize the mechanisms of resistance, consisting mainly of acquired genomic alterations in the MAPK and PI3K pathways and tyrosine kinase receptor alterations, but gene fusions, histological changes, or conformational changes in the kinase have also been described. In this paper, we review the development of KRAS G12C inhibitors in colorectal cancer as well as the main mechanisms of resistance.
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly
    Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma () -  Mar 31, 2024 - Abstract #SWOGSpring2024SWOG_Spring_38;    
    Participants must have progressed on prior therapy with fluoropyrimidine and/or oxaliplatin, given either for metastatic/locally advanced disease or as adjuvant therapy completed within the previous 12 months...Participants must not be receiving chronic antiplatelet therapy, including dipyridamole or clopidogrel, or similar agents...Two major protocol deviations were coded: one participant received reduced doses of all drugs for the first cycle in error, and another participant did not receive leucovorin and fluorouracil IV bolus during the first cycle...Of the 14 participants assessed on the Ramucirumab + Paclitaxel arm, four reported Grade 4 events, including neutropenia (4 participants), lung infection (1), and decreased white blood cell count (1). Of the 13 participants assessed on the FOLFIRI arm, one Grade 5 toxicity (Death NOS) has been reported and two participants had Grade 4 neutropenia.
  • ||||||||||  tilatamig samrotecan (AZD9592) / AstraZeneca
    Enrollment change, Monotherapy:  EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov) -  Mar 28, 2024   
    P1,  N=162, Recruiting, 
    Of the 13 participants assessed on the FOLFIRI arm, one Grade 5 toxicity (Death NOS) has been reported and two participants had Grade 4 neutropenia. N=108 --> 162
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal, Gene Expression Profile:  Gene Expression Profile-Guided Personalized Intraperitoneal Chemotherapy for Gastric Cancer Peritoneal Carcinomatosis. (Pubmed Central) -  Mar 28, 2024   
    The median life expectancy in the basic group was 16.8 (13.7 - 18.8) months, in the control group it was 12.5 (11.3 - 13.1) months (P < 0.001). Developing algorithms of personalized systemic and intraperitoneal chemotherapy in patients with GC with synchronous carcinomatosis, based on the analysis of molecular genetic characteristics of the tumor and metastases, allows to improve the long-term results of combined treatment.
  • ||||||||||  Yutuo (zimberelimab) / Arcus Biosci, Gilead, domvanalimab (AB154) / Arcus Biosci, Gilead, quemliclustat (AB680) / Arcus Biosci, Gilead
    Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  EDGE-Gastric: A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (clinicaltrials.gov) -  Mar 27, 2024   
    P2,  N=360, Recruiting, 
    Developing algorithms of personalized systemic and intraperitoneal chemotherapy in patients with GC with synchronous carcinomatosis, based on the analysis of molecular genetic characteristics of the tumor and metastases, allows to improve the long-term results of combined treatment. N=200 --> 360 | Trial completion date: Nov 2025 --> Jun 2027 | Trial primary completion date: Sep 2025 --> Sep 2026
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Enrollment change, Trial completion date, Trial primary completion date:  Peri-operative SLOG for Localized Pancreatic Cancer (clinicaltrials.gov) -  Mar 27, 2024   
    P2,  N=64, Recruiting, 
    Follow up in 1 year revealed no local orbital tumor recurrence with excellent visual acuity and no diplopia in primary gaze. N=40 --> 64 | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2024
  • ||||||||||  Enrollment open, Circulating tumor DNA:  ctDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial) (clinicaltrials.gov) -  Mar 27, 2024   
    P2,  N=60, Recruiting, 
    N=40 --> 64 | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2024 Not yet recruiting --> Recruiting
  • ||||||||||  M9140 / EMD Serono
    Trial completion date, Trial primary completion date, Metastases:  Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (clinicaltrials.gov) -  Mar 27, 2024   
    P1,  N=180, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: May 2025 --> Feb 2026 | Trial primary completion date: Apr 2024 --> Feb 2026
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Chemotherapy-induced pneumatosis intestinalis followed by hepatic portal venous gas. A case report. (Pubmed Central) -  Mar 25, 2024   
    We report here, a patient with liver metastases from colorectal cancer who developed PI followed by HPVG after treatment with 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6). Timely attention and management of gastrointestinal symptoms following chemotherapy are essential in the treatment of this type of patient.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Journal, Surgery:  A Case of Conversion Surgery for Stage ? ATP-Producing Gastric Cancer with Distant Metastasis (Pubmed Central) -  Mar 22, 2024   
    After 2 courses of systemic chemotherapy FOLFOX/nivolumab, total gastrectomy, D2 node dissection, splenectomy pancreas tail resection, cholecystectomy, hepatic resection, partial transverse colon resection, partial jejunum resection, Roux-en-Y reconstruction...The pathological efficacy evaluation was Grade 1a in the primary tumor. The patient has been recurrence-free for 9 months since the initial diagnosis.
  • ||||||||||  irinotecan / Generic mfg.
    Enrollment open:  XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial) (clinicaltrials.gov) -  Mar 22, 2024   
    P=N/A,  N=98, Recruiting, 
    The patient has been recurrence-free for 9 months since the initial diagnosis. Not yet recruiting --> Recruiting
  • ||||||||||  Trial completion date, Trial primary completion date:  SU2C ACT3: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer (clinicaltrials.gov) -  Mar 21, 2024   
    P3,  N=400, Recruiting, 
    Trial completion date: Sep 2029 --> Sep 2031 | Trial primary completion date: Jan 2029 --> Jan 2031 Trial completion date: Apr 2026 --> Dec 2027 | Trial primary completion date: Apr 2025 --> Dec 2026
  • ||||||||||  Review, Journal, Metastases:  Advances in Drug Therapy for Metastatic Pancreatic Ductal Adenocarcinoma. (Pubmed Central) -  Mar 18, 2024   
    For mPDAC, FOLFIRINOX or gemcitabine plus nab-paclitaxel are the current first-line treatments...Current understanding of the molecular signature and immune landscape of PDAC has motivated the emergence of different targeted and immune-based therapeutic approaches, some of which have shown promising results. The purpose of this review is to discuss the new targets and new drugs for mPDAC in terms of specific pathogenic factors such as metabolic vulnerability, DNA damage repair system, tumor microenvironment and immune system, in order to identify potential vulnerabilities in mPDAC patients and hopefully improve the prognosis of mPDAC patients.
  • ||||||||||  ibrilatazar (ABTL0812) / Ability Pharma
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  PanC-ASAP: ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study (clinicaltrials.gov) -  Mar 17, 2024   
    P1/2,  N=150, Completed, 
    Recognition of novel nirAEs can expedite treatment and potentially prevent progressive neurologic disability. Trial completion date: Sep 2028 --> Jan 2024 | Trial primary completion date: Dec 2024 --> Jan 2024 | Recruiting --> Completed
  • ||||||||||  elraglusib (9-ING-41) / Actuate Therap
    Trial completion date, Trial primary completion date, Metastases:  FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer (clinicaltrials.gov) -  Mar 15, 2024   
    P2,  N=70, Recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
  • ||||||||||  Enweida (envafolimab) / 3DMed, Ascletis, suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
    Trial completion date, Trial termination, Combination therapy, Metastases:  A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Mar 15, 2024   
    P2,  N=86, Terminated, 
    Not yet recruiting --> Recruiting Trial completion date: Dec 2023 --> Jul 2023 | Recruiting --> Terminated; The study was terminated due to the sponsor's research and development strategy adjustment.
  • ||||||||||  trabedersen (OT-101) - Autotelic, Oncotelic / Dragon Overseas JV
    Phase classification, Trial initiation date, Combination therapy, Metastases:  STOP-PC: A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer (clinicaltrials.gov) -  Mar 15, 2024   
    P2/3,  N=455, Not yet recruiting, 
    Trial completion date: Dec 2023 --> Jul 2023 | Recruiting --> Terminated; The study was terminated due to the sponsor's research and development strategy adjustment. Phase classification: P2b --> P2/3 | Initiation date: Dec 2023 --> May 2024
  • ||||||||||  DELTA RADIOMIC FEATURES PREDICT RESECTION MARGIN STATUS AND OVERALL SURVIVAL IN NEOADJUVANT-TREATED PANCREATIC CANCER PATIENTS (Hall A, Poster Hall - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_7565;    
    The model that combined preoperative clinical variables (pre-NAT CA19-9, the change in CA19-9 after NAT (?CA19-9), and DRF outperformed all the other models (clinical feature-based models and other radiomics feature-based models) in predicting OS (UTSW: 0.73; Humanitas: 0.66), DFS (UTSW: 0.75; Humanitas: 0.64), and PRMS (UTSW 0.73; Humanitas: 0.69) in both the discovery and validation cohorts. Conclusions Our externally validated model that incorporates delta radiomic features with preoperative clinical data shows promise as a pre-operative tool in predicting OS and DFS and in estimating the risk of an R0 resection in NAT-treated PDAC patients.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    LABTHERA-002, A LIVE BIOTHERAPEUTIC PRODUCT, IMPROVES THE FOLFOX-INDUCED CACHEXIA IN COLORECTAL CANCER MICE MODEL THROUGH GUT MICROBIOTA MODULATION. (Hall A, Poster Hall - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_7498;    
    We will result, which suggest that the microbiota promotes cytokine release from inflammatory response through control tight junction protein expression that are more highly expressed on gut epithelial cells. The above results suggest that changes in the gut microbiota caused by anticancer drugs may be closely involved in cachexia symptoms, and LABTHERA-002 has the potential to be a combination treatment to alleviate FOLFOX-induced cachexia symptoms.
  • ||||||||||  irinotecan / Generic mfg.
    NOVEL SN38 CONJUGATE TARGETS UNIQUELY TUMORS AND OUTPERFORMS IRINOTECAN (Hall A, Poster Hall - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_7167;    
    DZ-SN38 was significantly more effective in inhibiting tumor growth and metastasis in our animal models. DZ-SN38 is a unique cancer-targeting therapeutic that overcomes the toxicity of irinotecan and outperforms it in in vitro and in vivo models of pancreatic cancer.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    GOBLET CELL ADENOCARCINOMA AND RESPONSE TO TREATMENT - SINGLE CENTER EXPERIENCE OF A RARE MALIGNANCY (207B - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_6831;    
    Patients with stage II disease have modest 5-year survival with surgical resection and selective use of adjuvant chemotherapy. Patients with peritoneal metastases can have long-term survival when treated with a combination of systemic chemotherapy, cytoreductive surgery, and HIPEC, though the role of the treatment itself versus careful patient selection remains unknown.